Accessibility Menu
Aurinia Pharmaceuticals Stock Quote

Aurinia Pharmaceuticals (NASDAQ: AUPH)

$11.81
(-0.3%)
-0.03
Price as of October 22, 2025, 3:58 p.m. ET

KEY DATA POINTS

Current Price
$11.82
Daily Change
(-0.3%) $0.03
Day's Range
$11.69 - $11.86
Previous Close
$11.82
Open
$11.85
Beta
1.11
Volume
1,045,335
Average Volume
1,966,503
Market Cap
1.6B
Market Cap / Employee
$11.84M
52wk Range
$6.55 - $13.54
Revenue
-
Gross Margin
0.90%
Dividend Yield
N/A
EPS
$0.43
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Aurinia Pharmaceuticals Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
AUPH+65.13%-22.05%-4.86%+478%
S&P+15.06%+95.03%+14.29%+378%

Aurinia Pharmaceuticals Company Info

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$70.01M22.4%
Gross Profit$62.89M30.3%
Gross Margin89.84%5.4%
Market Cap$1.14B40.1%
Market Cap / Employee$8.80M0.0%
Employees130-56.7%
Net Income$21.51M2879.6%
EBITDA$34.31M734.3%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$53.00M58.7%
Accounts Receivable$40.09M57.1%
Inventory46.519.7%

Liabilities

Q2 2025YOY Change
Long Term Debt$64.62M-9.1%
Short Term Debt$17.21M15.4%

Ratios

Q2 2025YOY Change
Return On Assets11.82%21.2%
Return On Invested Capital-20.76%6.2%

Cash Flow

Q2 2025YOY Change
Free Cash Flow$44.97M185.0%
Operating Free Cash Flow$45.07M184.1%

Valuation

MetricQ4 2024Q1 2025Q2 2025YoY Change
Price to Earnings232.6429.1119.81-
Price to Book2.703.313.003.3345.97%
Price to Sales4.845.644.664.4812.71%
Price to Tangible Book Value2.743.353.043.3745.77%
Price to Free Cash Flow TTM37.1230.6918.2512.62-
Enterprise Value to EBITDA38.0374.5828.0527.15-80.70%
Free Cash Flow Yield2.7%3.3%5.5%7.9%-
Return on Equity-5.8%1.5%11.2%17.3%-230.24%
Total Debt$87.85M$79.37M$77.91M$81.83M-4.83%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.